OOIR: Observatory of International Research

Papers

(The H4-Index of Lung Cancer is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Prevalence and prognostic significance of interstitial lung abnormalities in lung cancer: A meta-analysis	146
Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study	125
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer	92
3 The Availability of Molecular Profiling Results at New Patient Review in NSCLC and the Impact on Patient Care	80
105 Implementation of a Lung Cancer Nurse Specialist 2WW Remote Outpatient Triage Clinic – Optimising Patient Access and Assessment	79
66 Early Experiences of the Use of Combination Immunotherapy for the Treatment of Malignant Mesothelioma from 2022–2023 – Real-World Evidence of 1-Year Data from a Single UK Tertiary Cancer Centre	59
74 Is Age A Thing? Accessing Treatment for Pleural Mesothelioma	54
2 The role of cellular pathology departments in the improvement of turnaround times for lung adenocarcinoma biomarker testing	52
64 Variability in patient pathways and experiences of care in peritoneal mesothelioma	52
116 Health and Wellbeing days for Lung Cancer patients	50
133 Review of Advanced Lung cancer treatment in relation to the NLCA report	48
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England	48
119 Estimating the health benefits of introducing ctDNA next generation sequencing to the diagnostic pathway for advanced lung cancer: A modelling study	46
164 Participant recollection of recent imaging is unreliable for determining eligibility for lung cancer screening	45
216 Prolonged Localised Inflammatory Response following Bronchoscopic Thermal Vapour Ablation Therapy mimicking Lung Cancer	43
171 The impact of introducing a Targeted Lung Health Check on oncology services at Portsmouth Hospitals University NHS Trust	43
206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib	42
149 Stereotactic radiosurgery (SRS) for the treatment of brain metastases: Outcomes for lung cancer patients in South Wales	41
213 Selpercatinib in RET Fusion Lung Adenocarcinoma	40
219 Oesophageal EUS-guided Pericardiocentesis: A Therapeutic Conundrum in Patient with EGFR-positive Metastatic Lung Adenocarcinoma and Posterior Pericardial Tamponade	40
36 Summary of data for CT-guided percutaneous lung biopsy from West Yorkshire and Harrogate Cancer Alliance in 2021	40
48 Real world outcomes of a lung cancer genomic tumour advisory board: a single-centre experience in the United Kingdom	39
90 Real world Time on Treatment (rwToT) of Pembrolizumab in Stage IV NSCLC—a single centre experience	39
217 Atypical pseudoprogression in non-small cell lung cancer treated with pembrolizumab.	38
93 Evaluating real-world tepotinib-related toxicity data across five UK cancer units- A case-series	37

84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer	37
87 Overview of patients who complete two years of chemotherapy-immunotherapy for metastatic non-small cell lung cancer in Leicester	36
153 Lattice radiotherapy (LRT): Safely Dose Escalating Palliative Radiotherapy	36
130 A review of patients diagnosed with non-small cell lung cancer, stage I-II disease and a performance status of 0–1 over the past 10 years	35
111 Patient, professional and carer experiences of communicating a lung cancer diagnosis: A systematic review of qualitative evidence	35
136 Supporting the wellbeing of oncodriven lung cancer patients online: a qualitative study	35
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients	35
143 Using ProKnow to explore the incidence of radiation pneumonitis in relation to GTV size in Stage III Non-Small Cell Lung Cancer (NSCLC) concurrent Chemoradiotherapy (cCRT) patients and its impact	34
205 An update on the VIGILANCE study: Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer	34